Search results for "CHOD"

showing 10 items of 372 documents

Investigation into isoprenaline resistance in patients with obstructive lung disease

1974

12 patients with chronic obstructive lung disease have been studied in an investigation regarding the causes of resistance to isoprenaline. The effects of repeated intravenous doses of 10 µg isoprenaline were assessed by cross over comparison before and after infusions of isoprenaline and a placebo; the infusions lasted for 35 to 40 min and the amount of isoprenaline infused was 0.5 µg/min. Total resistance, thoracic gas volume (whole-body plethysmography) and heart rate (ECG) were measured. No decrease in bronchospasmolytic or positive chronotopic effects on single isoprenaline injections could be demonstrated after prolonged infusions of isoprenaline.

AdultMalemedicine.medical_specialtyDrug ResistanceDrug resistancePlaceboPlacebosElectrocardiographyHeart RateIsoprenalineInternal medicineHeart ratemedicineHumansPlethysmographInfusions ParenteralPharmacology (medical)Lung Diseases ObstructiveAgedPlethysmography Whole BodyAsthmaPharmacologyAnalysis of VarianceClinical Trials as Topicbusiness.industryAirway ResistanceIsoproterenolGeneral MedicineMiddle Agedmedicine.diseaseStimulation ChemicalObstructive lung diseaseAirway ObstructionBronchodilatationAnesthesiaInjections IntravenousCardiologyFemalebusinessmedicine.drugEuropean Journal of Clinical Pharmacology
researchProduct

Measurement of inflammatory mediators of eosinophils and lymphocytes in blood in acute asthma: serum levels of ECP influence the bronchodilator respo…

2002

The aim of this study was to assess the relevance of immunoinflammatory markers on the response to short acting β<sub>2</sub>-agonist in acute asthma exacerbation. Thus, we measured serum eosinophil cationic protein (ECP) levels and sIL-2R at acute exacerbation in 52 adult patients with atopic asthma, and assessed forced expiratory volume in 1 s (FEV<sub>1</sub>) before and after the administration of aerosolized salbutamol. After a cumulative dose of salbutamol causing a 10% improvement in FEV<sub>1</sub> from baseline [CD10, i.e. cumulative doses of salbutamol (800 µg) causing an improvement in FEV<sub>1</sub> from baseline to 10%] the patie…

AdultMalemedicine.medical_specialtyExacerbationAdolescentmedicine.drug_classImmunologyStatistics NonparametricRibonucleasesInternal medicineBronchodilatorForced Expiratory VolumemedicineImmunology and AllergyHumansAlbuterolAsthmaSkin TestsEosinophil cationic proteinCumulative dosebusiness.industryReceptors Interleukin-2General MedicineBlood Proteinsrespiratory systemEosinophilAdrenergic beta-AgonistsEosinophil Granule ProteinsImmunoglobulin EMiddle Agedmedicine.diseaseBlood proteinsAsthmarespiratory tract diseasesBronchodilator AgentsEndocrinologymedicine.anatomical_structureImmunologySalbutamolFemalebusinessmedicine.drugInternational archives of allergy and immunology
researchProduct

Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus.

1993

1. We have investigated the role of cyclic nucleotide phosphodiesterase IV (PDE IV) in the relaxation of human bronchus and guinea-pig trachea in vitro and in guinea-pigs in vivo. 2. Functional studies showed that the selective PDE IV inhibitors, rolipram and denbufylline, relaxed human and guinea-pig preparations in vitro. 3. Two clinically used xanthine non-selective PDE inhibitors, theophylline and pentoxifylline, were also effective in these preparations, but were much less potent than the selective agents used. 4. The rank order of potency for the four PDE inhibitors in both species was similar. 5. Biochemical studies indicated that PDE IV was the major PDE isoform present in the human…

AdultMalemedicine.medical_specialtyPhosphodiesterase InhibitorsGuinea PigsBiologyIn Vitro TechniquesPentoxifyllinechemistry.chemical_compoundTheophyllineIn vivoInternal medicinemedicineAnimalsHumansTheophyllineheterocyclic compoundsPentoxifyllineRolipramAgedPharmacologyCyclic nucleotide phosphodiesterasePhosphoric Diester HydrolasesIsoproterenolMiddle AgedXanthinemusculoskeletal systemAsthmaPyrrolidinonesBronchodilator AgentsCyclic Nucleotide Phosphodiesterases Type 4IsoenzymesBronchodilatationenzymes and coenzymes (carbohydrates)Disease Models AnimalEndocrinologychemistryEnzyme inhibitor3'5'-Cyclic-AMP PhosphodiesterasesXanthinesbiology.proteinFemalesense organsRoliprammedicine.drugcirculatory and respiratory physiologyResearch Article
researchProduct

Mid-Term Effectiveness of Behavioral and Psychodynamic Inpatient Treatments of Severe Obesity Based on a Randomized Study

2006

<i>Background:</i> The objective of this study was to compare the effectiveness of psychodynamic and behavioral inpatient treatments of severely obese patients regarding weight and distress. <i>Methods:</i> In a longitudinal study obese patients (body mass index, BMI ≧35) were randomly assigned to behavioral or to psychodynamic inpatient treatment. Mostly female (n = 267; 85%) obese patients with psychiatric and somatic comorbidity (age 20–64 years, BMI 35–74) were examined with standardized self-report scales on distress (SCL-90R), interpersonal problems (Inventory of Interpersonal Problems), eating behavior (Fragebogen zum Essverhalten) and body image (Fragebogen z…

AdultMalemedicine.medical_specialtymacromolecular substancesBody weightSeverity of Illness IndexBody Mass Indexlaw.inventionPsychiatric comorbidityRandomized controlled trialBehavior TherapylawSurveys and QuestionnairesmedicineHumansInterpersonal RelationsObesityBulimia NervosaPsychiatryApplied PsychologyApplication methodsbusiness.industryFollow up studiesGeneral MedicineMiddle AgedSevere obesityPsychodynamicsmedicine.diseaseObesityHospitalizationPsychotherapyPsychiatry and Mental healthClinical PsychologyFemalebusinessFollow-Up StudiesPsychotherapy and Psychosomatics
researchProduct

Biochemical interaction between effects of beclomethasone dipropionate and salbutamol or formoterol in sputum cells from mild to moderate asthmatics.

2005

Background:  Several in vitro studies demonstrate that corticosteroids and long-acting β2 agonists may have a complementary and synergistic mode of action on the inflammatory processes in asthma. Methods:  Sputum was induced in 20 mild to moderate asthmatic patients and the induced sputum cells (ISC) were cultured with beclomethasone dipropionate (BDP) 10−7 M, salbutamol 10−8 M and formoterol 10−8 M either alone or in combination, BDP plus salbutamol and BDP plus formoterol, for 24 h. We measured the levels of growth macrophages-colony stimulating factor (GM-CSF), released on activation normal T cells expressed and activated (RANTES) and interleukin-8 (IL-8), in the supernatant of stimulate…

AdultMalemedicine.medical_specialtymedicine.drug_classReceptor expressionImmunologySeverity of Illness IndexGlucocorticoid receptorReceptors GlucocorticoidInternal medicineFormoterol FumaratemedicineImmunology and AllergyHumansAlbuterolDrug InteractionsTissue DistributionAnti-Asthmatic AgentsChemokine CCL5Cells Culturedbusiness.industryInterleukin-8BeclomethasoneSputumGranulocyte-Macrophage Colony-Stimulating FactorBeclometasone dipropionaterespiratory systemMiddle AgedAsthmarespiratory tract diseasesBronchodilator AgentsEndocrinologyEthanolaminesSalbutamolCorticosteroidFormoterol FumarateDrug Therapy CombinationFemaleFormoterolReceptors Adrenergic beta-2businessEx vivomedicine.drugAllergy
researchProduct

Developing a prototype for short-term psychodynamic (supportive-expressive) therapy: An empirical study with the psychotherapy process Q-set.

2015

AbstractObjective: A Psychotherapy Process Q-set (PQS) prototype characteristic of short-term psychodynamic therapy (STPP) does not yet exist. Method: Experts in supportive-expressive (SE) therapy used the 100-Item PQS questionnaire to rate an ideal short-term SE therapy. Results: Agreement between raters was high (Cronbach's alpha = 0.94). The prototype for SE therapy showed a significant correlation with the psychoanalytic prototype, but with 28% of variance explained, the majority of variance of the former was not explained by the latter or vice versa. Furthermore, the SE prototype showed significant correlations with the cognitive-behavioral prototype and the prototype of interpersonal …

AdultPsychodynamic psychotherapyPsychotherapistCognitive Behavioral TherapyPsychotherapeutic Processes05 social sciencesVariance (accounting)Interpersonal communication050108 psychoanalysisPsychodynamicsExplained variation030227 psychiatry3. Good healthPsychoanalytic Therapy03 medical and health sciencesClinical Psychology0302 clinical medicineCronbach's alphaHumans0501 psychology and cognitive sciencesPsychologyExpressive therapySet (psychology)Psychotherapy PsychodynamicClinical psychologyPsychotherapy research : journal of the Society for Psychotherapy Research
researchProduct

GINA 2019: a fundamental change in asthma management

2019

GINA no longer recommends treating adults/adolescents with asthma with short-acting bronchodilators alone. Instead, they should receive symptom-driven (in mild asthma) or a daily corticosteroid-containing inhaler, to reduce risk of severe exacerbations.http://bit.ly/310LLzE

AdultPulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyAdolescentMild asthmaGlobal HealthAsthma managementAdministration InhalationHumansMedicineAnti-Asthmatic AgentsDisease management (health)Monitoring PhysiologicRandomized Controlled Trials as TopicAsthmaInhalationbusiness.industryInhalerDisease Managementmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesBudesonide/formoterolPractice Guidelines as TopicFundamental changebusinessmedicine.drugEuropean Respiratory Journal
researchProduct

Tiotropium add-on therapy reduces seasonal peaks of asthma worsening in adults with symptomatic severe asthma

2019

Despite the use of preferred controller therapies (including inhaled corticosteroids [ICS] with or without additional long-acting β2-agonists [LABAs]), a large proportion of patients with asthma have poor disease control, leaving them at risk of recurring symptoms and episodes of asthma exacerbations and worsening [1, 2]. Such problems can be triggered by many different environmental factors including pollutants, respiratory infections or allergens [3]. They may occur sporadically, but are often determined by seasons, mirroring seasonal patterns of allergen exposure and prevalence of respiratory viral infection [3, 4]. They can cause reduced quality of life, increase asthma burden [2, 3], a…

AdultPulmonary and Respiratory Medicinemedicine.medical_specialtySevere asthma03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Administration InhalationmedicineHumans030212 general & internal medicineTiotropium BromideAsthmaWork productivitybusiness.industryConflict of interestmedicine.diseaseAsthmaBronchodilator AgentsAdd on therapy030228 respiratory systemFamily medicineAbsenteeismDrug Therapy CombinationSeasonsALLERGEN EXPOSUREbusinessEuropean Respiratory Journal
researchProduct

Efficacy of short-term psychodynamic psychotherapy (STPP) with depressed breast cancer patients: results of a randomized controlled multicenter trial.

2014

BACKGROUND There is a lack of trials of psychodynamic treatments of depression in breast cancer patients. The purpose of this trial was to determine the efficacy of short-term psychodynamic psychotherapy (STPP) in non-metastatic breast cancer patients diagnosed with depression, one of the most frequent mental comorbidities of breast cancer. PATIENTS AND METHODS In a multicenter prospective trial, 157 breast cancer patients with comorbid depression were randomized to either individual STPP (intervention group, N=78) or 'treatment as usual' (control group, TAU, N=79). As our primary outcome measure, we hypothesized a higher rate of remission defined as no diagnosis of depression (Structured C…

Adultmedicine.medical_specialtyAdolescentBreast NeoplasmsHospital Anxiety and Depression ScaleYoung AdultBreast cancerQuality of lifeInternal medicineMulticenter trialmedicineHumansProspective StudiesPsychiatryDepression (differential diagnoses)AgedPsychodynamic psychotherapyIntention-to-treat analysisbusiness.industryDepressionHematologyMiddle Agedmedicine.diseaseComorbidityTreatment OutcomeOncologyQuality of LifeFemalebusinessPsychotherapy PsychodynamicAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol

2015

Abstract Long-acting β 2 -adrenoceptor agonists, formoterol and salmeterol, represent a milestone in the treatments of chronic obstructive lung diseases. Although no specific indications concerning the choice of one molecule rather than another are provided by asthma and COPD guidelines, they present different pharmacological properties resulting in distinct clinical employment possibilities. In particular, salmeterol has a low intrinsic efficacy working as a partial receptor agonist, while formoterol is a full agonist with high intrinsic efficacy. From a clinical perspective, in the presence of low β 2 -adrenoceptors availability, like in inflamed airways, a full agonist can maintain its b…

AgonistChronic ObstructiveIntrinsic activitymedicine.drug_classSocio-culturaleLABASettore MED/10 - Malattie Dell'Apparato RespiratorioPharmacologyPartial agonistPulmonary DiseaseAsthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterol; Internal MedicinePulmonary Disease Chronic Obstructiveimmune system diseasesFormoterol FumarateInternal MedicinemedicineHumansFormoterolSalmeterolSalmeterol XinafoateBronchodilator AgentAsthmaCOPDbusiness.industryChronic obstructive pulmonary diseaseMedicine (all)Asthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterolrespiratory systemmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeAnesthesiaFormoterolOnset of actionSalmeterolbusinessAsthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterol; Bronchodilator Agents; Formoterol Fumarate; Humans; Pulmonary Disease Chronic Obstructive; Salmeterol Xinafoate; Treatment Outcome; Internal MedicineHumanmedicine.drugEuropean Journal of Internal Medicine
researchProduct